NO20060568L - Anvendelse av et nytt eimeriagen og tilhorende protein - Google Patents

Anvendelse av et nytt eimeriagen og tilhorende protein

Info

Publication number
NO20060568L
NO20060568L NO20060568A NO20060568A NO20060568L NO 20060568 L NO20060568 L NO 20060568L NO 20060568 A NO20060568 A NO 20060568A NO 20060568 A NO20060568 A NO 20060568A NO 20060568 L NO20060568 L NO 20060568L
Authority
NO
Norway
Prior art keywords
protein
polynucleotide
eimeria
eimeriagen
new
Prior art date
Application number
NO20060568A
Other languages
English (en)
Inventor
Gisela Greif
Ralf Hosse
Juergen Krueken
Frank Wunderlich
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of NO20060568L publication Critical patent/NO20060568L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/012—Coccidia antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/455—Eimeria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Oppfinnelsen er relatert til et nytt oocyste sporocysteprotein (EtOS22) som tilhører parasitten av arten Eimeria tenella og til polynukleotidet som koder for dette proteinet, til vektorer som inneholder dette polynukleotidet, til celler som er transformert med disse vektorene, til antistoffer som er rettet mot proteinet, til vaksiner som omfatter polynukleotidet, proteinet, eller fragmenter av dette, og de ovenfor nevnte vektorene eller antistoffene rettet mot proteinet, og til anvendelsen av polynukleotid eller av polypeptid for å finne aktive forbindelser for å behandle en infeksjon med Eimeria og aktive forbindelser som er egnet for terapien av en infeksjon med Eimeria.
NO20060568A 2003-07-04 2006-02-03 Anvendelse av et nytt eimeriagen og tilhorende protein NO20060568L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10330235A DE10330235A1 (de) 2003-07-04 2003-07-04 Neues Eimeria Gen und Protein sowie deren Verwendung
PCT/EP2004/007080 WO2005005472A1 (en) 2003-07-04 2004-06-30 Use of a novel eimeria gene and corresponding protein

Publications (1)

Publication Number Publication Date
NO20060568L true NO20060568L (no) 2006-03-31

Family

ID=33521342

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060568A NO20060568L (no) 2003-07-04 2006-02-03 Anvendelse av et nytt eimeriagen og tilhorende protein

Country Status (13)

Country Link
US (1) US7691987B2 (no)
EP (2) EP2311859A1 (no)
JP (1) JP4594304B2 (no)
AR (1) AR045000A1 (no)
AU (1) AU2004255594B2 (no)
BR (1) BRPI0412323A (no)
CA (1) CA2531161A1 (no)
DE (1) DE10330235A1 (no)
MX (1) MXPA06000198A (no)
NO (1) NO20060568L (no)
NZ (1) NZ544451A (no)
WO (1) WO2005005472A1 (no)
ZA (1) ZA200510465B (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103096934A (zh) * 2010-03-09 2013-05-08 詹森生物科技公司 非水性高浓度低粘度混悬剂
US20110223208A1 (en) * 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
US9072668B2 (en) 2010-03-09 2015-07-07 Janssen Biotech, Inc. Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
MX358174B (es) * 2011-11-17 2018-08-08 Dsm Ip Assets Bv Uso de proteasas estables en medio acido en la alimentacion animal, preferentemente para incrementar el rendimiento de pollos de engorde vacunados contra la coccidiosis.
US9891231B2 (en) 2012-01-24 2018-02-13 University Of Massachusetts Soluble MANF in pancreatic β-cell disorders
CN103233017B (zh) * 2013-05-06 2014-11-05 扬州大学 毒害艾美耳球虫的配子体抗原gam22基因及其应用
CN111471107B (zh) * 2020-04-27 2023-04-18 中国农业大学 抗鸡球虫多价重组蛋白卵黄抗体及其制备方法和应用
CN112592961A (zh) * 2021-01-07 2021-04-02 山东科硕生物技术有限公司 一种核酸样本保存液及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187080A (en) * 1984-06-05 1993-02-16 Solvay & Cie S.A. DNA encoding an antigenic protein derived from Eimeria tenella and vaccines for prevention of coccidiosis caused by Eimeria tenella
ES2091861T3 (es) * 1985-12-03 1996-11-16 Solvay Proteinas antigenicas y vacunas que las contienen para la prevencion de la coccidiosis.
ZA893740B (en) * 1988-06-03 1990-02-28 Hoffmann La Roche Recombinant coccidiosis vaccines
JPH06504187A (ja) * 1990-09-12 1994-05-19 ジェネックス・コーポレーション 遺伝子操作されたコクシジウム症ワクチン

Also Published As

Publication number Publication date
US20070184054A1 (en) 2007-08-09
JP4594304B2 (ja) 2010-12-08
AU2004255594B2 (en) 2010-12-09
BRPI0412323A (pt) 2006-08-22
JP2008500003A (ja) 2008-01-10
NZ544451A (en) 2009-06-26
EP2311859A1 (en) 2011-04-20
US7691987B2 (en) 2010-04-06
EP1644407A1 (en) 2006-04-12
AR045000A1 (es) 2005-10-12
CA2531161A1 (en) 2005-01-20
DE10330235A1 (de) 2005-01-20
ZA200510465B (en) 2007-03-28
MXPA06000198A (es) 2006-03-21
WO2005005472A1 (en) 2005-01-20
AU2004255594A1 (en) 2005-01-20

Similar Documents

Publication Publication Date Title
NO20060568L (no) Anvendelse av et nytt eimeriagen og tilhorende protein
El Ridi et al. Schistosoma mansoni ex vivo lung-stage larvae excretory–secretory antigens as vaccine candidates against schistosomiasis
AU2003244855A1 (en) Method to enhance an immune response of nucleic acid vaccination
WO2006036550A3 (en) Listeria-based and llo-based vaccines
EA200700849A1 (ru) Первичная/бустерная противомалярийная вакцина
CO5700788A2 (es) Composiciones y metodos para inmunoterapia especifica de wt1
WO2006068663A3 (en) Vaccine compositions for treating coronavirus infection
EA200901060A1 (ru) Новый способ и композиции
UY26783A1 (es) Antígenos de estreptococo.
HK1087006A1 (en) Coccidial vaccine and methods of making and using same
AR039460A1 (es) Factores camp quimericos
BR112022007158A2 (pt) Agentes imunomodulatórios de il-2 em combinação com inibidores do ponto de verificação imunológico
ES2090085T3 (es) Vacuna contra la coccidiosis.
AU2002319501A1 (en) Materials and methods relating to improved vaccination strategies
Saidi et al. Identification and characterization of a cathepsin L-like cysteine protease from Rhipicephalus (Boophilus) annulatus
EP1556513A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES MEDIATED BY THE HUMANE PAPILLOMA VIRUS
ATE473756T1 (de) Pharmazeutische zusammensetzung zur behandlung oder prävention von ovarialkrebs
PT1290160E (pt) Polipeptideos pellino humanos
DE60235021D1 (de) Rekombinante, 56 bzw. 82 kda grosse antigene aus gametozyten von eimeria maxima codierende nukleinsäuren und ihre verwendungen
AR051853A1 (es) Vacuna para aumentar el crecimiento basada en epitopes neutralizantes
Konnai et al. Suppression of cell proliferation and cytokine expression by HL‐p36, a tick salivary gland‐derived protein of Haemaphysalis longicornis
US10105424B2 (en) Cooperia vaccine
WO2003093416A3 (en) Protective antigens for the control of ixodes species infestations
DE60235044D1 (de) REKOMBINANTES, 250 kDa GROSSES ANTIGEN AUS SPOROZOITEN/MEROZOITEN VON EIMERIA MAXIMA CODIERENDE NUKLEINSÄUREN UND IHRE VERWENDUNGEN
ATE542885T1 (de) Impfungs-ausführungsarten

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application